We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

The search for a treatment for malaria, which kills more than a million people every year, mainly in sub-Saharan Africa, has been complicated by the emergence of drug resistance.

One new drug, however, which has already been approved for sale by five African nations, is touted by its Canadian manufacturer as safe and exceptionally effective.

But in this article Diane Martindale reports that the drug, known as Malarex, is provoking suspicion in the malaria research community. At best, some researchers claim, the drug has not been adequately tested for safety or efficacy. At worst, others say, it may be a fraud.

Link to The Scientist article

Related topics